| 11/19/2024 | BKEMHY | S&P raises Teva
|
| 10/10/2024 | BKEMHY | Moody’s raises Teva view to positive
|
| 9/18/2024 | BKEMHY | Fitch raises Teva
|
| 6/24/2024 | BKCVEMHY | S&P turns Teva outlook to positive
|
| 3/7/2024 | BKEMHY | Fitch revises Teva outlook to positive
|
| 5/31/2023 | BKCVEMHY | S&P turns Teva outlook to stable
|
| 3/6/2023 | BKCVEMHY | S&P assigns BB- to Teva notes
|
| 3/1/2023 | BKCVEMGNHY | Fitch assigns BB- to Teva notes
|
| 2/27/2023 | BKCVDDEMIGPV | Market Commentary: Triumph, Teva on deck; Tegna tanks on FCC acquisition opposition; TransDigm, Uniti improve
|
| 7/29/2022 | BKCVEMGNHY | S&P lifts Teva outlook to positive
|
| 7/27/2022 | BKCVDDEMIGPV | Market Commentary: Avient prices; secondary surges post-Fed; cross-over credits in demand; Teva gains on settlement
|
| 12/15/2021 | BKCVEMGNHY | Moody's turns Teva outlook to stable
|
| 12/6/2021 | BKCVEMGNHY | Fitch revises Teva view to stable
|
| 11/4/2021 | BKCVDDEMIGPV | Market Commentary: DCP Midstream, Asbury Automotive price; Teva active; Continental gains; CommScope sinks
|
| 11/3/2021 | BKCVDDEMIGPV | Market Commentary: Junk secondary unmoved by Fed tapering statement; Teva flat; Jane Street on a 101-handle
|
| 11/1/2021 | BKCVDDEMIGPV | Market Commentary: Mr. Cooper, Navient price; loanDepot gains on earnings beat; PG&E active
|
| 9/3/2020 | BKCVEMHY | S&P trims Teva
|
| 11/18/2019 | BKCVDDEMIGPV | Market Commentary: iHeart, Boyd, Mattel, MSCI add-on price; Prestige Brands trades up
|
| 11/14/2019 | BKCVEM | Moody’s rates Teva notes Ba2
|
| 11/13/2019 | BKCVEM | S&P rates Teva notes BB
|
| 11/8/2019 | BKCVDDEMIGPV | Market Commentary: Wesco PattonAir downsizes; Albertsons improves; LPL up; Teva active; Wildhorse rebounds
|
| 11/8/2019 | BKCVDDEMIGPV | Market Commentary: Wesco PattonAir downsizes; Albertsons improves; LPL up; Teva active; Wildhorse rebounds
|
| 10/24/2019 | BKCVEM | S&P places Teva ratings on CreditWatch negative
|
| 10/21/2019 | BKCVDDEMIGPV | Market Commentary: United Rentals, KB Home price; newer notes trade; Teva lifted; Coty falls; WeWork higher
|
| 10/18/2019 | BKCVDDEMIGPV | Market Commentary: Neptune Energy adds; Evoca prices; Thursday issuance higher; Teva up; WeWork better
|
| 10/16/2019 | BKCVDDEMIGPV | Market Commentary: Merlin, Speedway price; new Charter notes rise; pharma names up; Sprint, T-Mobile higher
|
| 8/28/2019 | BKCVDDEMIGPV | Market Commentary: Pharma space under pressure; Rackspace higher; Tallgrass negative; oil names rise
|
| 8/27/2019 | BKCVDDEMIGPV | Market Commentary: Pharma names see negativity; Range Resources varies; GTT declines
|
| 8/14/2019 | BKCVEM | Moody’s revises Teva view to negative
|
| 8/13/2019 | BKCVDDEMIGPV | Market Commentary: Post Labor Day pipeline eyed; Tenet bounces off lows; Teva drops; Goodyear Tire rises
|
| 7/23/2019 | BKCVDDEMIGPV | Market Commentary: JBS USA, Five Point add-on price; Teva in focus; LSC Communications craters
|
| 7/5/2019 | BKCVDDEMIGPV | Market Commentary: Trading light; Altice USA backs off gains; Teva active but flat; funds add $800 million
|
| 6/7/2019 | BKCVEM | Fitch downgrades Teva
|
| 6/3/2019 | BKCVDDEMIGPV | Market Commentary: Multi-Color, Grubhub on tap; Neiman Marcus, GCI price; Teva in focus, gains; Altice up
|
| 5/29/2019 | BKCVDDEMIGPV | Market Commentary: CNO Financial prices; Frontier gains; Teva’s downward spiral continues; CRC drops
|
| 5/28/2019 | BKCVDDEMIGPV | Market Commentary: CNO Financial, GoDaddy on tap; Fiat up on merger; Teva drops post settlement
|
| 5/15/2019 | BKCVDDEMIGPV | Market Commentary: Transocean prices; Berry on tap; VistaJet active; Teva, Commscope under pressure
|
| 5/13/2019 | BKCVDDEMIGPV | Market Commentary: Eldorado on tap; Bausch Health weakens; Charter below par; Weatherford, Teva down
|
| 4/10/2019 | BK | Teva obtains new $2.3 billion revolver in tranches due 2022, 2024
|
| 2/15/2019 | BKCVEM | S&P revises Teva view to negative
|
| 2/14/2019 | BKCVEM | S&P lowers Teva view to negative
|
| 1/4/2019 | BKCVDDEMIGPV | Market Commentary: Risk-on sentiment returns; CDX sees largest single-day gain in four years; energy outperforms
|
| 1/3/2019 | BKCVDDEMIGPV | Market Commentary: No new deals in sight; trading volume light; Western Digital active; Qorvo drops; Teva up
|
| 11/1/2018 | BKBWCVEMHY | Israel’s Teva is using majority of cash flow to reduce leverage to 3x
|
| 10/11/2018 | BKCVDDEMIGPV | Market Commentary: Millicom prices; TransDigm rises on acquisition; energy mixed; Teva Pharaceutical improves
|
| 8/15/2018 | BKCVEM | Fitch affirms Teva Pharmaceutical
|
| 7/27/2018 | BKCVDDEMIGPV | Market Commentary: Hi-Crush prices, euro primary active; Party City’s new issue lower; Teva slides
|
| 7/26/2018 | BKCVDDEMIGPV | Market Commentary: Party City prices; Teva improves; Aleris acquired; SuperValu bought; funds off $548 million
|
| 7/20/2018 | BKCVDDEMIGPV | Market Commentary: Comstock prices; Bruin carried over; secondary trading light; IHS Markit eyed; Teva active
|
| 3/16/2018 | BKCVDDEMIGPV | Market Commentary: Tullow, Husky lead busy primary; Mattel trades on Toys shutdown; Teva still trades under par
|
| 3/7/2018 | BKCVDDEMIGPV | Market Commentary: Upsized Teva megadeal prices; new Ball notes busiest; CIT trades up; Frontier mostly up
|
| 3/6/2018 | BKCVDDEMIGPV | Market Commentary: Three-part CIT drive-by leads deal parade; Ball, William Lyons, Buena Vista also price
|
| 2/28/2018 | BKCVEM | S&P rates Teva notes BB
|
| 2/28/2018 | BKCVEM | Moody’s applies Ba2 to Teva notes
|
| 2/8/2018 | BK | S&P downgrades Teva, debt
|
| 2/2/2018 | BK | S&P might downgrade Teva
|
| 2/1/2018 | BK | Teva amends covenants in credit agreements for added flexibility
|
| 1/12/2018 | BKCVEM | Moody’s downgrades Teva to Ba2
|
| 12/14/2017 | BKBWCVHYIG | Teva to use all available cash flow to cut debt until end of 2020
|
| 12/14/2017 | BKCVEMIG | Moody’s reviews Teva Pharmaceutical
|
| 11/6/2017 | BKCVEMIG | Fitch downgrades Teva to BB
|
| 11/3/2017 | BKCVEMIG | S&P revises Teva to negative
|
| 9/20/2017 | BKCVEMIG | S&P downgrades Teva
|
| 9/19/2017 | BK | Teva amends credit facilities to provide greater covenant flexibility
|
| 8/4/2017 | BKCVIG | Fitch downgrades Teva to BBB-
|
| 8/4/2017 | BKCVEMIG | Moody's downgrades Teva
|
| 2/3/2017 | BKCVEMIG | S&P: Teva Pharmaceutical outlook to negative
|
| 8/2/2016 | BKCVEMIG | Moody’s downgrades Teva to Baa2
|
| 7/22/2016 | BKCVEMIG | Fitch rates Teva bonds BBB
|
| 7/20/2016 | BKCVEMIG | Fitch downgrades Teva, rates bond BBB
|
| 7/18/2016 | BKCVEMIG | S&P rates Teva notes BBB
|
| 7/18/2016 | BKCVEMIG | Moody’s rates Teva notes Baa2
|
| 7/13/2016 | BKBWEMIG | Teva planned net debt funding for Allergan purchase down by $4 billion
|
| 7/13/2016 | BKCVEMIG | S&P downgrades Teva
|
| 11/25/2015 | BKCVEMIG | S&P rates Teva loan BBB+
|
| 11/18/2015 | BK | Teva signs $5 billion term loan agreement, $4.5 billion revolver
|
| 8/3/2015 | BKEMIG | Israel’s Teva details commitments for $33.75 billion in facilities
|
| 7/31/2015 | BKEMIG | Israel’s Teva gets financing commitments for up to $33.75 billion
|
| 7/28/2015 | BKCVEMIG | S&P lowers Teva Pharmaceutical
|
| 7/27/2015 | BKBWEMIGLM | Teva Pharmaceuticals to obtain up to $27 billion of debt to buy Allergan’s generics business
|
| 7/27/2015 | BKCVEMIG | Moody’s cuts Teva Pharmaceutical to Baa1
|
| 4/22/2015 | BK | S&P downgrades Chromaflo
|
| 4/22/2015 | BK | S&P downgrades Chromaflo
|
| 4/22/2015 | BKCVEMIG | Fitch: Teva on watch after merger news
|
| 4/22/2015 | BKCVEMIG | S&P: Teva on watch after Mylan deal announced
|
| 4/21/2015 | BKCVEMIG | Moody's changes Teva outlook to negative
|
| 3/31/2015 | BKCVEMIG | Moody's: Teva unchanged
|
| 3/24/2015 | BKCVEMIG | Moody's rates Teva notes A3
|
| 3/24/2015 | BKCVEMIG | S&P rates Teva notes A-
|
| 3/24/2015 | BKCVEMIG | Fitch assigns BBB+ to Teva bond
|
| 2/19/2015 | BK | Fitch upgrades JetBlue
|
| 2/19/2015 | BKCVEMIG | Moody’s revises Teva to stable
|
| 12/11/2013 | BKCVEM | Fitch downgrades Teva
|
| 6/13/2013 | BKCVEM | Moody's: Teva view to negative
|
| 12/18/2012 | BK | Teva gets expanded $3 billion five-year revolver with Citi and HSBC
|
| 12/13/2012 | BK | Teva Pharmaceutical to pay down $700 million loan via note offerings
|
| 12/13/2012 | BKCVEM | Fitch rates Teva notes A-
|
| 12/6/2011 | BKCVEMIG | Teva has 'robust' rating, 'significant' cash flow for deleveraging
|
| 11/7/2011 | BK | Teva to repay $3.75 billion short-term debt used for Cephalon purchase
|
| 11/2/2011 | BK | Teva borrows approximately $8.5 billion during third-quarter 2011
|
| 5/3/2011 | BKCACVHY | Moody's confirms Valeant
|
| 3/18/2010 | BKBWCV | Teva to use cash, lines of credit to fund Ratiopharm acquisition
|
| 10/27/2008 | BKSS | Barr Pharmaceuticals amends credit facilities ahead of merger with Teva
|
| 7/18/2008 | BKCVEMIG | Moody's may upgrade Barr, affirms Teva
|
